Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als symbols : Nrxp save search
NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer
Published: 2022-03-18 (Crawled : 10:00) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 0.0%
H: 4.94%
C: -2.78%
als
NRx Pharmaceuticals Announces Leadership Transition
Published: 2022-03-09 (Crawled : 04:00) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 5.12%
H: 32.58%
C: 23.6%
als ces
NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment
Published: 2022-02-15 (Crawled : 14:00) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 1.66%
H: 9.15%
C: -0.65%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.01%
H: 0.65%
C: 0.35%
covid-19 zyesami aviptadil health als covid yes enroll
NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules
Published: 2022-02-03 (Crawled : 01:00) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -8.2%
H: 7.22%
C: 2.75%
als ces nasdaq
NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -4.49%
H: 0.34%
C: -0.34%
als nasdaq
NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -0.57%
H: 0.0%
C: -8.68%
covid-19 zyesami treatment aviptadil als expansion respiratory covid
NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics
Published: 2022-01-12 (Crawled : 23:00) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -1.05%
H: 1.91%
C: -6.6%
als therapeutics collaboration
NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 Vaccine
Published: 2022-01-07 (Crawled : 23:00) - globenewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
| Email alert
Add to watchlist
covid-19 als covid vaccine brilife
NRx Pharmaceuticals Submits Emergency Use Authorization Application to US FDA for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
Published: 2022-01-05 (Crawled : 10:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 1.52%
H: 0.0%
C: 0.0%
covid-19 zyesami treatment fda aviptadil als risk application covid media authorization merge emergency use authorization
NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use
Published: 2022-01-03 (Crawled : 13:30) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -3.14%
H: 0.0%
C: 0.0%
aviptadil als patent
NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
Published: 2021-12-29 (Crawled : 12:30) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 10.22%
H: 4.84%
C: 0.2%
covid-19 zyesami treatment aviptadil als risk covid media therapy breakthrough therapy designation
NRx Pharmaceuticals Added to the Nasdaq® Biotech Index
Published: 2021-12-15 (Crawled : 12:30) - globenewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -0.53%
H: 1.78%
C: -3.2%
NDAQ | $60.35 0.47% 0.46% 3.1M
|
Finance
|
| O: -1.62%
H: 0.82%
C: 0.79%
nasdaq als biotech index index biotech iot
NRx Pharmaceuticals Announces New, Favorable Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -3.08%
H: 0.0%
C: 0.0%
covid-19 zyesami aviptadil als covid
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
RWOD | $9.54 19.3% 16.18% 6.1M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.